If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Trading Update

7 Nov 2016 07:00

RNS Number : 4343O
Ideagen PLC
07 November 2016
 

7 November 2016

Ideagen plc

("Ideagen" or the "Company")

 

Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2016.

 

The Board is pleased to report that trading has remained strong in the first half of the financial year.

 

Revenue and adjusted EBITDA are expected to show a significant increase over the same period last year through a combination of organic growth and the acquisition of Covalent. The Group expects to report organic revenue growth of approximately 16% together with a small contribution from Covalent which was acquired in August 2016. The integration of Covalent is now complete and the Company expects an increased level of contribution in the second half. Consequently, the Company continues to trade in line with market expectations for the full year to 30 April 2017.

 

Cash generation in the period was strong and the Company maintains a robust balance sheet with no debt. The cash balance at the period end was £4.8 million (30 April 2016: £6.3 million), after the payment of £3.8 million for acquisitions and associated costs.

 

David Hornsby, Chief Executive Officer of Ideagen, commented: "This has been a good start to the financial year. Strong trading has been driven by demand across all key vertical markets and continued momentum with our cloud-based Enlighten solution. The market opportunity remains large and long term, and consequently, the Board is optimistic about the Group's continued growth prospects."

 

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

Alma PR

Tel: 020 8004 4218

Hilary Buchanan

Josh Royston

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.LN). Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in eGRC (Enterprise Governance, Risk and Compliance) and Healthcare solutions for organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete content lifecycle solutions that enable organisations to meet their Regulatory and Quality Compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 2,200 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVZLFBQFFFFBQ
Date   Source Headline
10th Aug 201711:45 amRNSDirector Dealing
28th Jul 20174:19 pmRNSDirector Dealing
18th Jul 20177:00 amRNSFinal Results
12th Jun 20178:45 amRNSHolding(s) in Company
18th May 20173:19 pmRNSExercise of Options and Total Voting Rights
17th May 20177:00 amRNSPre-Close Trading Update
11th May 20172:21 pmRNSHolding(s) in Company
31st Mar 20171:10 pmRNSDirector/PDMR Shareholding
30th Mar 201711:48 amRNSHolding(s) in Company
30th Mar 20177:00 amRNSNew Aviation SaaS contracts worth £1.8m
28th Mar 20179:16 amRNSHolding(s) in Company
27th Mar 20176:05 pmRNSHolding(s) in Company
23rd Mar 201710:49 amRNSDirectors' Dealing & Total Voting Rights
23rd Mar 20177:00 amRNSAcquisition and Placing to raise £10m
1st Mar 201711:47 amRNSExercise of Options and Total Voting Rights
1st Mar 20177:00 amRNSHolding(s) in Company
24th Feb 20172:28 pmRNSExercise of Options and Total Voting Rights
24th Feb 201712:20 pmRNSHolding(s) in Company
21st Feb 20177:00 amRNSExercise of Options and Total Voting Rights
1st Feb 201711:44 amRNSHolding(s) in Company
26th Jan 20178:29 amRNSDividend Timetable
24th Jan 20177:01 amRNSDirectorate Changes
24th Jan 20177:00 amRNSInterim Results
9th Dec 20167:00 amRNSAcquisition of IPI Solutions Ltd
7th Dec 20162:14 pmRNSHolding(s) in Company
28th Nov 20164:55 pmRNSHolding(s) in Company
24th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 201611:37 amRNSHolding(s) in Company
7th Nov 20167:00 amRNSTrading Update
2nd Nov 20167:00 amRNSExercise of Options and Total Voting Rights
28th Oct 20161:26 pmRNSResult of AGM
13th Oct 20167:00 amRNSNew Contract Wins worth £1.2m
11th Oct 20167:00 amRNSExercise of Options and Total Voting Rights
6th Oct 20167:00 amRNSNotice of AGM
6th Sep 20167:00 amRNSAcquisition of Logen Ltd.
1st Sep 20167:00 amRNSExercise of Options and Total Voting Rights
12th Aug 20167:00 amRNSExercise of Options and Total Voting Rights
8th Aug 20167:00 amRNSAcquisition of Covalent Software Ltd
29th Jul 20167:00 amRNSExercise of Options and Total Voting Rights
19th Jul 20163:28 pmRNSDividend Timetable
19th Jul 20167:00 amRNSFinal Results
12th Jul 20167:00 amRNSNotice of Results
5th Jul 20167:00 amRNSHolding(s) in Company
29th Jun 20161:56 pmRNSHolding(s) in Company
18th May 20167:00 amRNSPre-Close Trading Update
5th May 20167:00 amRNSExercise of Options and Total Voting Rights
29th Apr 20167:00 amRNSNew contract wins in life science sector
29th Mar 20167:00 amRNSExercise of Options and Total Voting Rights
18th Mar 20167:00 amRNSRe £4.9m Contract and Trading Update
29th Jan 20168:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.